Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANRO NASDAQ:FGEN NASDAQ:FTLF NASDAQ:IPHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$6.21-0.1%$3.86$1.60▼$15.04$167.63M2565,403 shs162,561 shsFGENFibroGen$11.35-0.4%$10.75$4.50▼$21.94$45.85M0.7674,015 shs16,699 shsFTLFFitLife Brands$20.68-0.4%$17.79$9.83▼$20.92$194.14M0.6519,368 shs4,260 shsIPHAInnate Pharma$2.07+2.7%$2.06$1.29▼$3.51$189.89M0.0488,276 shs2,423 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience+4.36%+52.08%+59.08%+137.40%-44.71%FGENFibroGen+2.98%-5.16%+2.15%+55.10%+38.86%FTLFFitLife Brands+3.49%+5.38%+8.52%+57.39%+27.05%IPHAInnate Pharma+1.53%+0.60%-2.45%+9.94%-7.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$6.21-0.1%$3.86$1.60▼$15.04$167.63M2565,403 shs162,561 shsFGENFibroGen$11.35-0.4%$10.75$4.50▼$21.94$45.85M0.7674,015 shs16,699 shsFTLFFitLife Brands$20.68-0.4%$17.79$9.83▼$20.92$194.14M0.6519,368 shs4,260 shsIPHAInnate Pharma$2.07+2.7%$2.06$1.29▼$3.51$189.89M0.0488,276 shs2,423 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience+4.36%+52.08%+59.08%+137.40%-44.71%FGENFibroGen+2.98%-5.16%+2.15%+55.10%+38.86%FTLFFitLife Brands+3.49%+5.38%+8.52%+57.39%+27.05%IPHAInnate Pharma+1.53%+0.60%-2.45%+9.94%-7.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANROAlto Neuroscience 2.44Hold$9.8057.56% UpsideFGENFibroGen 2.00Hold$43.00277.19% UpsideFTLFFitLife Brands 3.00Buy$23.0010.79% UpsideIPHAInnate Pharma 2.00Hold$6.50226.63% UpsideCurrent Analyst Ratings BreakdownLatest FGEN, IPHA, FTLF, and ANRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ANROAlto NeuroscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025FGENFibroGenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025FTLFFitLife BrandsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/8/2025IPHAInnate PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/6/2025FTLFFitLife BrandsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/29/2025ANROAlto NeuroscienceChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.009/27/2025ANROAlto NeuroscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025FGENFibroGenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025FTLFFitLife BrandsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/27/2025IPHAInnate PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/24/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.00(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANROAlto NeuroscienceN/AN/AN/AN/A$5.62 per shareN/AFGENFibroGen$29.62M1.55N/AN/A($50.89) per share-0.22FTLFFitLife Brands$64.47M3.02$1.05 per share19.80$3.93 per share5.28IPHAInnate Pharma$21.77M8.43N/AN/A$0.11 per share18.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANROAlto Neuroscience-$61.43M-$2.39N/AN/AN/AN/A-44.34%-36.73%11/11/2025 (Estimated)FGENFibroGen-$47.58M-$0.38N/AN/AN/A-3.86%N/A-27.34%11/11/2025 (Estimated)FTLFFitLife Brands$8.98M$0.8424.7118.87N/A12.63%21.70%13.45%N/AIPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/AN/ALatest FGEN, IPHA, FTLF, and ANRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FTLFFitLife Brands$0.18$0.18N/A$0.18$16.17 million$16.13 million8/13/2025Q2 2025ANROAlto Neuroscience-$0.57-$0.65-$0.08-$0.65N/AN/A8/11/2025Q2 2025FGENFibroGen-$2.25-$3.38-$1.13-$1.88$2.88 million$1.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANROAlto NeuroscienceN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANROAlto Neuroscience0.1818.4318.43FGENFibroGenN/A1.041.02FTLFFitLife Brands0.151.710.81IPHAInnate Pharma3.522.21N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANROAlto NeuroscienceN/AFGENFibroGen72.71%FTLFFitLife Brands2.32%IPHAInnate Pharma0.16%Insider OwnershipCompanyInsider OwnershipANROAlto Neuroscience11.13%FGENFibroGen3.07%FTLFFitLife Brands61.40%IPHAInnate Pharma31.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANROAlto NeuroscienceN/A27.08 million24.06 millionN/AFGENFibroGen5704.04 million3.92 millionOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableIPHAInnate Pharma22092.18 million62.79 millionNot OptionableFGEN, IPHA, FTLF, and ANRO HeadlinesRecent News About These CompaniesInnate Pharma (NASDAQ:IPHA) Earns Sell (E+) Rating from Weiss RatingsOctober 9 at 4:35 AM | marketbeat.comInnate Pharma management to meet with BTIGOctober 2, 2025 | msn.comInnate Pharma FY2025 EPS Forecast Increased by HC WainwrightSeptember 22, 2025 | marketbeat.comLeerink Partnrs Forecasts Innate Pharma Q3 EarningsSeptember 22, 2025 | marketbeat.comInnate Pharma (NASDAQ:IPHA) Stock Rating Lowered by Leerink PartnrsSeptember 20, 2025 | marketbeat.comLeerink Partners Downgrades Innate Pharma S.A. - Depositary Receipt (IPHA)September 19, 2025 | msn.comInnate Pharma (NASDAQ:IPHA) Given "Market Perform" Rating at Leerink PartnersSeptember 19, 2025 | marketbeat.comHC Wainwright Reaffirms Neutral Rating for Innate Pharma (NASDAQ:IPHA)September 19, 2025 | marketbeat.comHC Wainwright & Co. Downgrades Innate Pharma S.A. - Depositary Receipt (IPHA)September 18, 2025 | msn.comInnate Pharma S.A. (NASDAQ:IPHA) Q2 2025 Earnings Call TranscriptSeptember 18, 2025 | insidermonkey.comInnate Pharma downgraded to Market Perform from Outperform at LeerinkSeptember 17, 2025 | msn.comInnate Sheds 30% of Staff, Narrows Pipeline Focus Amid ‘Challenging Funding Environment’September 17, 2025 | biospace.comBInnate to lose 30% of workforce, including CSO, in focus on 'highest-value assets'September 17, 2025 | fiercebiotech.comFEarnings Scheduled For September 17, 2025September 17, 2025 | benzinga.comInnate Pharma S.A. (IPHA) Q2 2025 Earnings Call TranscriptSeptember 17, 2025 | seekingalpha.comInnate Pharma Reports First Half 2025 Business Update and Financial ResultsSeptember 17, 2025 | businesswire.comInnate Pharma SA (IPHA) Q2 2025 Earnings Report Preview: What To Look ForSeptember 16, 2025 | finance.yahoo.comInnate Pharma Announces Its Participation in the 25th Edition of the European Midcap EventSeptember 15, 2025 | businesswire.comInnate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Down 25.8% in AugustSeptember 10, 2025 | marketbeat.comInnate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business UpdateSeptember 10, 2025 | businesswire.comInnate Pharma Announces Its Participation in the BTIG Virtual Biotechnology ConferenceJuly 29, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFGEN, IPHA, FTLF, and ANRO Company DescriptionsAlto Neuroscience NYSE:ANRO$6.20 -0.01 (-0.08%) As of 11:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.FibroGen NASDAQ:FGEN$11.35 -0.05 (-0.44%) As of 11:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.FitLife Brands NASDAQ:FTLF$20.68 -0.09 (-0.41%) As of 11:11 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Innate Pharma NASDAQ:IPHA$2.06 +0.06 (+2.74%) As of 11:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
